UMR1177: Drugs and Molecules for Living Systems


Therapeutic Innovation : Discovery Across Boundaries

U1177 (formerly U761), directed by Pr. Benoit Deprez, is dedicated to drug design, discovery and selection.

The Lab's mission is to design and study compounds that modulates selected molecular targets in a desired way to treat infectious and metabolic diseases.
Our projects engage researchers across physical, chemical and biological sciences to trade ideas and knowledge and sincerely endeavor to validate new therapeutic concepts with drug prototypes and bring drugs candidates to the clinic.


1. Developing cutting edge methods for quantitative pharmacology (High Content Screening, Pharmacokinetics)
2. Designing the next generation of anti-TB antibiotics : ethionamide boosters.
3. Deciphering the role(s) of Insulin Degrading Enzyme in diabetes with several families of modulators.
4. Modulating the molecular interplay between intestine, liver and muscles with TGR5 ligands to treat diabetes.
5. Developing small chemical modulators of antigenic presentation.

We are open to any type of collaboration with biologists or chemist from academia and industry where medicinal chemistry, in vitro pharmacology and pharmacokinetics enable or accelerate the translation of new therapeutic concept into drug discovery.

Our researchers are committed to the highest standards of scientific quality and integrity in everything they do. We use up-to date electronic lab books to sustainably capitalize knowledge and facilitate collaborations between multiple research sites.

Most of our researchers are also faculty members who teach in PharmD and MSc courses in pharmacy, drug discovery, medicinal chemistry, organic chemistry, and R&D strategies.

U1177 has received the above national accreditations for:

  • PAI for Equipex Imaginex BioMed
  • Prize for innovating enterprise APTΞEUS
  • Ibisa label for the screening, ADME and chemistry platform (CDithem)

Latest Publications

Chapuis, J., et al Alzheimer’s genetic risk factor FERMT2. Acta Neuropath.,2016. doi:1-12.10.1007/s00401-016-1652-z

Bauters, D., et al. ADAMTS5 & adipogenesis Thromb Haemost,2016, 116(4). doi:10.1160/th16-01-0015

Prevet, H., et al. Microwave-assisted synthesis of fragments . Tetrahedron Letters,2016,57(26):2888-2894. doi:10.1016/j.tetlet.2016.05.065

Letronne, F., et al ADAM30 in Alzheimer's Disease. EBioMedicine,2016: in press. doi:10.1016/j.ebiom.2016.06.002 OPEN ACCESS

Probst, N. P., et al. Palladium-free Sonogashira-type cross-coupling reaction. Tet. Lett.,2016, 57(10): 1066-1070. doi:10.1016/j.tetlet.2016.01.070

Bosc, D., et al. KTGS in drug discovery and chemical biology. Fut. Med. Chem.2016: in press. doi:10.4155/fmc-2015-0007 OPEN ACCESS

Broeders, E. M., et al. Chenodeoxycholic Acid Increases BAT Activity. Cell Metabolism,2015, 22(3): 418-426.

Deprez-Poulain, R., et al Catalytic site inhibition of IDE induces glucose intolerance in mice. Nature Comm.,2015, 6.
doi:10.1038/ncomms9250 OPEN ACCESS

Latest Press & News

BioVersys & TBboost team laureates of the Innovation Prize 2016 read more

Read more on future seminars and events

More press articles and releases

Master enrollment started for 2016-2017

Master enrollement has started. Apply here.

The program of the Master for the field of "drug design, synthesis, evaluation and selection of bioactive molecules", is available below.


Contact us for enrollement!